RAPID Alliance™Research Consortium
Research to Optimize Medication Therapies*including medications, vaccines, pharmacogenomics, digital therapeutics, over the counter medications, and related therapies
A project in the National Science Foundation Center for Health Organization Transformation at the University of Louisville
In Collaboration with the Frazier Polypharmacy Program at the University of Louisville
Non-optimized medication therapies are one of the most significant challenges in US healthcare today
Tens of millions of people in the US affected each year
$528 billion in potentially-avoidable health spending
An evolving global challenge
The RAPID Alliance is using new science to speed up processes of co-creating transformational solutions
The RAPID Alliance Research Consortium is part of of the RAPID Alliance / STAR Study at the National Science Foundation Center for Health Organization Transformation at the University of Louisville. It is being organized using new science (e.g. service-dominant logic, service- ecosystem design science and implementation science) and methods (e.g. Scalable Transformational Action Research (STAR) and the Research Regatta method supported by advanced collaboration technologies). Learn more.
Our Current Research Priorities
RAPID Alliance research priorities are co-created with community members. Priorities for 2021 are based on the RAPID Alliance 2021 Study.
Co-creating an ecosystem-level, evidence-based strategic framework and plan and prioritized national research agenda for optimizing medication and vaccine use for US populations from 2022 - 2030 while saving up to $528 billion annually in likely-avoidable health spending
Read the RAPID Alliance 2021 Report
In 2020, the RAPID Alliance research team, with support from the National Science Foundation Center for Health Organization Transformation at the University of Louisville and Sanofi, conducted a national study to identify priority strategies with potential to strengthen the capacity of the US Pharmacist and Pharmacy sector to act to protect and improve health and wellbeing for people living in the US during and after the COVID-19 pandemic. This report provides a roadmap for moving forward in 2021.
Who Should Join?
Anyone who is interested in doing more to optimize medications and related therapies in the US can any of our studies. After joining you will gain immediate access to selected member-only resources.
Join the Practice Community
Leaders from all sectors of healthcare interested in optimizing medication and related therapies for people living in the US are welcome to join the practice community.
Practice community members help identify problems, and provide support and input to researchers who do fast-track research to help solve them.
Join the Research Community
Established researchers and students from leading research universities and institutes interested in optimizing medication and related therapies for people living in the US are welcome to join the research community.
Research community members participate in fast-track, large-scale research studies to help practice community members solve their hardest challenges.
Our 2021 studies are being co-created in collaboration with our Practice Council and Research Council Members
The 2020 study was conducted in collaboration with our 2020 Research Panel Participants
Additional support provided by the National Science Foundation Center for Health Organization Transformation and supporting industry members
Thank you to all